The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Oral isotretinoin for acne: a complete overview
Abstract
INTRODUCTION: Acne is one of the most common and widespread skin conditions, affecting the health as much as patients' quality of life. A wide variety of treatments for acne, topical and systemics, could be prescribed, depending on its degree of severity. Isotretinoin, a derivative of retinol, has been widely used for the treatment of severe forms of acne and those forms not responding to conventional treatments. In literature, there are several studies describing its efficacy, also reporting side-effects related to the drug; therefore, this has led the scientific community to request further studies qualifying its characteristics and comparing its efficacy and safety with other classic acne treatments, as well as with different treatment regimes, in order to find the dose with the best efficacy/safety ratio. AREAS COVERED: The aim of this article is to provide a complete overview on the use of oral isotretinoin for the treatment of acne describing the efficacy, safety, and tolerability of the drug. EXPERT OPINION: Oral isotretinoin represents a valid therapeutic alternative in treating severe and mild-to-moderate acne lesions, also reducing scarring damage. There are no standardized protocols regarding the use of oral isotretinoin and its association with other therapies; however, the correct patient selection and a tailored treatment protocol according to acne lesions severity and type should be considered in order to obtain optimal results.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“isotretinoin reduces the size and secretion of sebaceous glands, decreases surface and ductal level of sebumdependent C. acnes indirectly, inhibits comedogenesis by normalizing keratinocyte keratinization, and possesses anti-inflammatory properties. 251”
From Guidelines of care for the management of acne vulgaris (2024) · cites this paper as [251]
Citations
Cites
TFOS DEWS II Definition and Classification Report
Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C.-K., Liu, Z., Nelson, J. D., Nichols, J. J., Tsubota, K., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.008 · Cited by 3,383
TFOS DEWS II Diagnostic Methodology report
Wolffsohn, J. S., Arita, R., Chalmers, R., Djalilian, A., Dogru, M., Dumbleton, K., Gupta, P. K., Karpecki, P., Lazreg, S., Pult, H., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.001 · Cited by 2,122
Hay, R. J., Johns, N. E., Williams, H. C., Bolliger, I. W., Dellavalle, R. P., Margolis, D. J., Marks, R., Naldi, L., Weinstock, M. A., Wulf, S. K., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.446 · Cited by 1,706
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597 · cited 1×
“addition, in the USA the strict pregnancy prevention program iPLEDGE is mandatory [18].”
Background(2007) · The Ocular Surface · doi:10.1016/s1542-0124(12)70085-x · Cited by 565
European Evidence‐based (S3) Guidelines for the Treatment of Acne
Nast, A., Dréno, B., Bettoli, V., Degitz, K., Erdmann, R., Finlay, A. Y., Ganceviciene, R., Haedersdal, M., Layton, A., López‐Estebaranz, J. L., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04374.x · Cited by 426
Thiboutot, D. M., Dréno, B., Abanmi, A., Alexis, A. F., Araviiskaia, E., Barona Cabal, M. I., Bettoli, V., Casintahan, F., Chow, S., da Costa, A., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.078 · Cited by 418 · cited 1×
“continuing isotretinoin until full clearance, plus an additional month, independent of cumulative dose [22].”
BackgroundEuropean evidence-based (S3) guideline for the treatment of acne - update 2016 - short version
Nast, A., Dréno, B., Bettoli, V., Bukvic Mokos, Z., Degitz, K., Dressler, C., Finlay, A. Y., Haedersdal, M., Lambert, J., Layton, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13776 · Cited by 393 · cited 1×
“aged <12 years could not be excluded [19,20].”
BackgroundClayton, J. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1407936 · Cited by 377
A clinical evaluation of acne scarring and its incidence
LAYTON, A. M., HENDERSON, C. A., & CUNLIFFE, W. J. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01200.x · Cited by 361
Research works printed but not linked: 12
- Al Muqarrab F, 2022, Dermatol Ther, 9, e15311
- Webster GF, 2014, J Drugs Dermatol, 13, 665
- Del Rosso JQ, 2019, J Clin Aesthet Dermatol, 12, 13
- Zaenglein AL, 2020, J Clin Aesthet Dermatol, 13, 15
- Pandey D, 2019, Kathmandu Univ Med J (KUMJ), 17, 14
- Hasibur MR, 2013, Mymensingh Med J, 22, 42
- Wahab MA, 2008, J Pak Assoc Derma, 18, 9
- Gollnick HP, 2001, Eur J Dermatol, 11, 538
- Del Rosso JQ, 2013, J Drugs Dermatol, 12, 626
- Magin P, 2005, Br J Gen Pract, 55, 134
- Hughes RA, 1993, J Rheumatol, 20, 1241
- Krishna S, 2012, J Am Acad Dermatol, 66, AB19
Cited by
Guidelines of care for the management of acne vulgaris
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.017 · Cited by 518
Skin Pigmentation Types, Causes and Treatment—A Review
Thawabteh, A. M., Jibreen, A., Karaman, D., Thawabteh, A., & Karaman, R. (2023) · Molecules · doi:10.3390/molecules28124839 · Cited by 233
The Role of the Skin Microbiome in Acne: Challenges and Future Therapeutic Opportunities
Niedźwiedzka, A., Micallef, M. P., Biazzo, M., & Podrini, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111422 · Cited by 99
Advances in polymeric nano-delivery systems targeting hair follicles for the treatment of acne
Lei, Y., Jiang, W., Peng, C., Wu, D., Wu, J., Xu, Y., Yan, H. J., & Xia, X. (2024) · Drug Delivery · doi:10.1080/10717544.2024.2372269 · Cited by 30
“…clinical efficacy, but it also has more severe adverse reactions, such as gastrointestinal discomfort, liver toxicity, and fetal malformations (tolino et al., 2020; Kemeriz et al., 2021; villani et al., 2022). therefore, topical treatment is more suitable for patients with mild to moderate acne.”
BackgroundZhang, L., Yang, Y., Wang, B., Zhao, Y. F., Wang, P., Liu, J., Yang, J., Wu, Y., Lv, T., Wei, Z., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.07.1023 · Cited by 27
Metadata
- Authors
- Villani, A., Nastro, F., Di Vico, F., Fabbrocini, G., Annunziata, M. C., & Genco, L.
- Affiliations
- University of Naples Federico II (IT)
- Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- Corresponding author
- Villani, Alessia
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2022-07-21
- Volume
- 21
- Issue
- 8
- Pages
- 1027-1037
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W4285793277
- Cited by
- 42
- References
- 98
- Citations by year
- 2026: 12 · 2025: 10 · 2024: 11 · 2023: 7 · 2022: 2
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Keywords
- isotretinoin, oral isotretinoin, acne, severe acne, retinoids, treatment efficacy, drug safety, tolerability, acne scars, patient selection, treatment protocols, dose optimization
- MeSH terms
- Acne Vulgaris, Administration, Oral, Dermatologic Agents, Humans, Quality of Life, Isotretinoin, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral isotretinoin for acne: a complete overview. https://app.cochat.ai/papers/10.1080/14740338.2022.2102605
- The paper
- Villani, A., Nastro, F., Di Vico, F., Fabbrocini, G., Annunziata, M. C., & Genco, L. (2022). Oral isotretinoin for acne: a complete overview. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2022.2102605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.